IDR-1002 in the news again

IDR-1002, a synthetic host defence peptide, is a potential candidate for the treatment of bacterial infections and the consequent inflammatory response due to its potent immunomodulatory activity, of great interest to the emerging issue of antimicrobial resistance in the farming sector.  In a new study by Sebők et al, using IDR-1002 supplied by Isca, the effects of IDR-1002 were investigated in a chicken hepatocyte‒non-parenchymal cell co-culture.  IDR-1002 had complex effects on the regulation of the hepatic innate immunity, increasing the levels of both RANTES and M-CSF, suggesting it plays a role in the modulation of macrophage differentiation, also reflected by reduced concentrations of IL-6 and IL-10. The pro-inflammatory cytokine release triggered by the bacterial cell wall component LTA was ameliorated by concomitantly applied IDR-1002, based on the levels of IL-6, chicken chemotactic and angiogenic factor CXCLi2 and interferon-γ.  The production of Nrf2, an essential transcription factor in the antioxidant defence pathway, was increased after IDR-1002 exposure, while protein carbonyl (PC) levels were also elevated. These findings suggest that IDR-1002 affects the interplay of the cellular immune response and redox homeostasis, and represents a promising approach to the treatment of bacterially induced inflammation in chickens.

See all Isca antimicrobial peptides >
See all product categories for immunology research >